Ac-SDKP dosage: reported doses and schedule
An experimental repair peptide with old human studies, but no proven healing dose.
Also called: AcSDKP, Goralatide, Seraspenide, N-acetyl-seryl-aspartyl-lysyl-proline, Thymosin beta-4 fragment 1–4, TB4-Frag.
Healing and repair peptides · Endogenous tetrapeptide; thymosin beta-4 N-terminal fragment.
Typical reported dose: 500 mcg once a day in the morning
- One SC dose: human PK: 128 nmol/kg once SC, about 62.4 mcg/kg. one exposure; no repeated schedule, under the skin. Studied in a trial. Studied in: Six healthy volunteers; pharmacokinetics only. (source)
- One IM dose: human PK: 128 nmol/kg once IM, about 62.4 mcg/kg. one exposure; no repeated schedule, into muscle. Studied in a trial. Studied in: Six healthy volunteers; pharmacokinetics only. (source)
- 12-hour infusion: human PK: 128 nmol/kg total over 12 hours IV, about 62.4 mcg/kg. one exposure; no repeated schedule, into a vein. Studied in a trial. Studied in: Six healthy volunteers; pharmacokinetics only. (source)
- 48-hour infusion: cancer PK: 51.3–513 nmol/kg total IV over 48 hours, about 25.0–250.1 mcg/kg. one 48-hour infusion; cohort dose range, into a vein. Studied in a trial. Studied in: Five patients receiving chemotherapy. (source)
- 15-minute metabolism test: 1.12 mcg/kg/min IV for 15 minutes; total 16.8 mcg/kg. one 15-minute IV infusion per test session, into a vein. Studied in a trial. Studied in: 24 normotensive adults divided by ACE genotype. (source)
- One poster: 500 mcg each morning: 500 mcg SC each morning, alongside BPC-157 500 mcg. once daily in the morning, under the skin. Reported by users, rare report. Studied in: One repeat forum poster; identity and independent product testing unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Ac-SDKP
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA warning on the risks of importing unapproved peptide products, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis: MedlinePlus Medical Encyclopedia, MedlinePlus · MedlinePlus
- Cellulitis: MedlinePlus Medical Encyclopedia, MedlinePlus
- GORALATIDE, NIH NCATS
- GORALATIDE, FDA
- Recognizing medical emergencies: MedlinePlus Medical Encyclopedia, MedlinePlus
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.